RECRUITING

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

NCT07143513•Amgen

View on ClinicalTrials.gov

Summary

The primary objective of this study is to characterize the safety profile of sotorasib.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adult (≥ 18 years) as of the index date.
•KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
•Received at least 1 dose of sotorasib.
•Receipt of at least 1 prior systemic therapy before use of sotorasib.
•Obtained ICF, if required.

Exclusion Criteria

•Documentation of being a non-Chinese ethnicity.

Locations (3)

Boao Evergrande International Hospital

Qionghai, Hainan, China

Boao Super Hospital

Qionghai, Hainan, China

Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine Hainan Boao Research Hospital

Qionghai, Hainan, China

Key Dates

Start Date

August 11, 2025

Primary Completion Date

February 28, 2026

Completion Date

June 30, 2026

Last Updated

September 12, 2025

Enrollment

115

ESTIMATED participants

Conditions

Non-Small Cell Lung Cancer

Interventions

Sotorasib

DRUG

Contacts

Amgen Call Center

CONTACT

866-572-6436 medinfo@amgen.com

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248

Non-small Cell Lung Cancer

View study

RECRUITINGPHASE3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITING

PHASE2/PHASE3